AstraZeneca Pharma India Limited — Important, 04-12-2024: Updates

The company has received an order from the Income-tax Appellate Tribunal (ITAT) for the assessment years 2017-18 and 2018-19, following an appeal against the final assessment order from the Tax Officer. The ITAT granted complete relief on two corporate tax grounds. However, regarding the transfer pricing issue, the ITAT has remitted the matter back to the Assessing Officer for further review in accordance with its directions. The potential financial implication from this ruling could lead to a favorable tax impact estimated at approximately Rs. 35.01 Crore. The company plans to coordinate with the Assessing Officer to ensure compliance with the ITAT’s guidance. Investors should monitor this situation closely for updates on the final resolution.